FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:409-411 January 25, 2007 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ullmann, A. J. Related Article by Cornely, O. A. PubMed Citation

Invasive fungal diseases contribute substantially to death and illness associated with the prolonged, profound neutropenia resulting from intensive chemotherapy for hematologic cancers and from myeloablation for allogeneic hematopoietic stem-cell transplantation. In addition, the development of graft-versus-host disease (GVHD) puts transplant recipients at risk for infection for several weeks or months after engraftment.¹ Given the high mortality associated with invasive fungal diseases and our inability to recognize active cases reliably, it is not surprising that prophylaxis is perceived as a sensible therapeutic approach.

More than a decade ago, fluconazole was shown to be effective for preventing candida infection.² However, aspergillus species . . . [Full Text of this Article]

Source Information

From the Department of Blood Transfusion and Transplant Immunology and the Department of Hematology, University Medical Center St. Radboud, Nijmegen, the Netherlands.

This article has been cited by other articles:

• Bulpa, P., Dive, A., Sibille, Y. (2007). Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J 30: 782-800 [Abstract] [Full Text]  
• (2007). Posaconazole Superior to Fluconazole for Preventing Aspergillosis. JWatch Infect. Diseases 2007: 1-1 [Full Text]